Clinical Trial

The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

Study acronym: LAKE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
Protocol Amendment History 3 changes
notable Trial sites expanded: 5 -> 10 locations 2026-08-11
critical Recruitment opened 2026-07-11
notable Trial sites expanded: 0 -> 5 locations 2026-07-11
Trial Details
NCT Number NCT07671924
Lead Sponsor Trevi Therapeutics
Conditions Refractory Chronic Cough
Enrollment 100 participants
Start Date 2026-06-22
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-10